Clinical trial

Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

NCT01733589

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-11-01

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2012-11-01Date precision: month

Registry last updated2017-07-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Stage III Non-small-Cell Lung Cancerunresolved

Interventions

Recombinant human endostatinDRUG

Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cyclesDRUG

cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cyclesDRUG

laboratory biomarker analysisOTHER

CT perfusion imagingOTHER

Sponsors & collaborators

Zhejiang Cancer Hospitallead sponsor

Chinese Academy of Medical Sciencescollaborator

Fudan Universitycollaborator

Peking University Cancer Hospital & Institutecollaborator

Tianjin Medical University Cancer Institute and Hospitalcollaborator

Shandong Cancer Hospital and Institutecollaborator

Jiangsu Cancer Institute & Hospitalcollaborator

Fujian Cancer Hospitalcollaborator

The First People's Hospital of Lianyungangcollaborator

Mapped research locations

HangzhouZhejiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01733589 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.